Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2800 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Biosimilar Infliximab (CT-P13) after Switching from Originator Infliximab: Results from the 26-Week Open Label Extension of a Randomized Norwegian Trial
Guro Løvik Goll¹, Kristin Kaasen Jørgensen², Joe Sexton¹, Inge C Olsen³, Nils Bolstad⁴, Merete Lorentzen⁵, Espen A. Haavardsholm⁶, Cato Mork⁷, Jorgen Jahnsen⁸ and Tore K Kvien⁹, ¹Dept Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ⁵Dept of Dermatology, Rikshospitalet, Oslo, Norway, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept of cancer and Molecular medicine, Norwegian University of Science and Technology, Trondheim, Norway, ⁸Dept of Gastroenterology, Akershus University Hospital, Lorenskog, Norway, ⁹Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) , Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…
Abstract Number: 603 • 2017 ACR/ARHP Annual Meeting
Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials
Philip J Mease¹, Dafna D Gladman², Arthur Kavanaugh³, Priscila Nakasato⁴, Benoit Guerette⁴, Lichen Teng⁴ and Peter Nash⁵, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of California, San Diego, School of Medicine, La Jolla, CA, ⁴Celgene Corporation, Summit, NJ, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: The PALACE 1, 2, and 3 trials evaluated the efficacy and safety of apremilast (APR) in subjects with active psoriatic arthritis (PsA) despite prior…
Abstract Number: 997 • 2017 ACR/ARHP Annual Meeting
Incidence and Clinical Characteristics of Active Tuberculosis in a Cohort of Patients with Inflammatory Arthritis Treated with TNF-Inhibitors
Ana Maria Gheorghiu¹, Alexandru Garaiman², Alexandra Radu², Alina Soare³, Victoria Arama⁴, Dragos Bumbacea⁵, Rucsandra Dobrota⁶, Raida Oneata⁷, Simona Pintilie², Mihaela Milicescu⁷, Ioan Ancuta⁷, Andrei Martin², Mariana Sasu¹, Claudia Ciofu¹, Liviu Macovei¹, Victor Stoica⁷, Mihai Bojinca⁷ and Carina Mihai⁸, ¹Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, CANTACUZINO HOSPITAL, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Infectious Diseases 1 Department, Matei Bals National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁵Department of Pneumology, Elias Emergency University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ⁸Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose: Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives: To assess the incidence of active TB and the efficacy of…
Abstract Number: 604 • 2017 ACR/ARHP Annual Meeting
Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies
Philip J Mease¹, Dafna D Gladman², Juan J. Gomez-Reino³, Stephen Hall⁴, Arthur Kavanaugh⁵, Eric Lespessailles⁶, Georg Schett⁷, Maria Paris⁸, Lichen Teng⁸ and Jürgen Wollenhaupt⁹, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain, ⁴Monash University, CabriniHealth, Melbourne, Australia, ⁵University of California, San Diego, School of Medicine, La Jolla, CA, ⁶University of Orleans, Orleans, France, ⁷Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁸Celgene Corporation, Summit, NJ, ⁹Schön Klinik Hamburg-Eilbek, Klinik fur Rheumatologie, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, regulates immune activity in psoriatic arthritis (PsA) patients. We evaluated the long-term safety of APR treatment for…
Abstract Number: 1256 • 2017 ACR/ARHP Annual Meeting
Uptake of Influenza and Pneumococcal Vaccination in Inflammatory Arthritis
Kieran Murray¹ and Douglas J. Veale², ¹Rheumatology, Rheumatology Specialist Registrar, Dublin 4, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose: Inflammatory arthritides such as RA and PsA increase infection risk. The Centre for Disease Control and Prevention (CDC) recommends vaccination against i. influenza for…
Abstract Number: 613 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies
Hervé Bachelez¹, Christopher EM Griffiths², Kim Papp³, Stephen Hall⁴, Joseph F Merola⁵, Steven R Feldman⁶, Majed Khraishi⁷, Anna Tallman⁸, Huaming Tan⁹ and Ming-Ann Hsu⁹, ¹Sorbonne Paris Cité Université Paris Diderot, AP-HP Hôpital St. Louis, Paris, France, ²Dermatology Centre, University of Manchester, Manchester, United Kingdom, ³Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁴Emeritus Research, Melbourne, Australia, ⁵Harvard Medical School, Boston, MA, ⁶School of Medicine, Wake Forest University, Winston-Salem, NC, ⁷Memorial University of Newfoundland, St. John's, NF, Canada, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Up to 42% of patients (pts) with psoriasis…
Abstract Number: 1428 • 2017 ACR/ARHP Annual Meeting
Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Fang Shen¹, Jennifer F. Nemeth², Brian Jones¹, Ann Cai¹, Shannon Hitchcock³, Thai Dinh², Ravi Malaviya¹ and Tatiana Ort¹, ¹Immunology, Janssen R&D, Spring House, PA, ²Janssen Biotech, Janssen R&D, Spring House, PA, ³Immunology, Janssen R&D, Springhouse, PA
Background/Purpose: Tumor necrosis factor alpha (TNFa) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including Rheumatoid Arthritis (RA) and…
Abstract Number: 614 • 2017 ACR/ARHP Annual Meeting
Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Alexis Ogdie¹, Kurt de Vlam², Iain B. McInnes³, Philip J Mease⁴, Philip Baer⁵, Tatjana Lukic⁶, Kenneth Kwok⁶, Cunshan Wang⁷, Ming-Ann Hsu⁷ and Anna Maniccia⁶, ¹Division of Rheumatology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UZ Leuven, Leuven, Belgium, ³Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Baer Weinberg MPC, Scarborough, ON, Canada, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), which has also been evaluated in other inflammatory rheumatic diseases…
Abstract Number: 1453 • 2017 ACR/ARHP Annual Meeting
Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Charlotte Traverson¹, Amandine Tubery¹, Charlotte Hua², Françoise Barchechath-Flaisler¹, Cédric Lukas³, Bernard Combe², Jacques Morel² and Cécile Gaujoux-Viala⁴, ¹Rheumatology, Nîmes University Hospital, Nîmes, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France
Background/Purpose: The addition of biological (b) and new targeted synthetic (ts) DMARDs agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of…
Abstract Number: 616 • 2017 ACR/ARHP Annual Meeting
Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies
Gerd R. Burmester¹, Oliver FitzGerald², Kevin Winthrop³, Valderilio F Azevedo⁴, William F C Rigby⁵, Keith S Kanik⁶, Cunshan Wang⁶, Pinaki Biswas⁷, Thomas Jones⁸, Sujatha Menon⁶, Niki Palmetto⁷ and Ricardo Rojo⁶, ¹Charité - University Medicine Berlin, Berlin, Germany, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Oregon Health & Science University, Portland, OR, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). We describe the safety profile of tofacitinib from integrated Phase (P)3…
Abstract Number: 1559 • 2017 ACR/ARHP Annual Meeting
Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Leonieke van Mens¹, Sadaf Atiqi², Inka Fluri², Marleen van de Sande³, Arno van Kuijk⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: With expanding therapeutic possibilities for the treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to…
Abstract Number: 617 • 2017 ACR/ARHP Annual Meeting
Comparing Tofacitinib Safety Profile in Patients with Psoriatic Arthritis in Clinical Studies with Real-World Data
Jeffrey R. Curtis¹, Huifeng Yun¹, Oliver FitzGerald², Kevin Winthrop³, Valderilio F Azevedo⁴, Gerd R. Burmester⁵, William F C Rigby⁶, Keith S Kanik⁷, Ricardo Rojo⁷, Sujatha Menon⁷, Cunshan Wang⁷, Pinaki Biswas⁸, Thijs Hendrikx⁹ and Niki Palmetto⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Oregon Health & Science University, Portland, OR, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Two Phase 3 studies have been completed (NCT01877668;…
Abstract Number: 1826 • 2017 ACR/ARHP Annual Meeting
Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS) Related Remission: 2-Year Results from a Phase 3 Study
Laura C Coates¹, Dafna D Gladman², Peter Nash³, Oliver FitzGerald⁴, Arthur Kavanaugh⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Kevin Ding⁷ and Corine Gaillez⁸, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Toronto Western Hospital, Toronto, ON, Canada, ³University of Queensland, Brisbane, Australia, ⁴St Vincent's University Hospital, Dublin, Ireland, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) disease activity score (PASDAS) assessing multiple facets of PsA was demonstrated to distinguish treatment effect, perform better in statistical terms than…
Abstract Number: 10L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman¹, William Rigby², Valderilio F Azevedo³, Frank Behrens⁴, Ricardo Blanco⁵, Andrzej Kaszuba⁶, Elizabeth Kudlacz⁷, Cunshan Wang⁷, Sujatha Menon⁷, Thijs Hendrikx⁸ and Keith S Kanik⁷, ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, ⁴Johann Wolfgang Goethe University, Frankfurt, Germany, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁶Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…
Abstract Number: 629 • 2016 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Klaus Krüger¹, GR Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius, München, Germany, ²Charité – University Medicine Berlin, Berlin, Germany, ³Rheumazentrum, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has shown its efficacy and safety in various randomized clinical trials with patients eligible for clinical studies. Data from patient-reported outcomes (PROs)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].